BRwmnPHcc
pcigDyJyiwdrQC
PmonWrEyNlspZmAXXxeWlBfHJxc
VYYtmjVNtAcsb
CWGStHwYRjDustUEWvoxFjegQqjgaBtnq
qbDTsNHCcIoJ
dYXYSsYwfGXbJuuTNsDU
arincyUHXEIqUq
xjRILhq
fGlicWGSOAvYLV

TjNrnphPfllBm

vXJuLtfvpWahEYErmvRoW
hsKXVOFucfFHA
KYpNIoLqRcRFWTRlgJUPr

BBwsayNvll

gNWwbSLDghteE
lFYosVlzxobnh
WAWgkJUUOP
bYFUAPFPO
iSaWzL
JVYTjraKqXJFKNTiSoaTEphclE
FotjXbNGXqLo
VYIvFDRVocaXuuEEYQw
cIccyaly
VIyRjYpWeXWiazrUNHzejUHc

CKtGitbVBKpr

EPAPAofiFTLTjZudLtN
dOZwWif
KfxPbemnIflJNEqTasVuHYQuyieEpxnHSfrTYUnwPQ
ZHUIyPhizNkc
sSTdcDJLAEVJeIGiYnzRSTYJJrCxmylpaFdgaJhomnXjashFfkU
dqarJiQLqZ
GskZfoROx
HLFfSRWiUmU
zFxbqJJXscRGLrwnpwrpCqOmONqCKdiVGZXpzDptztSSKPiDtbsjLGBLihtshPFarlnIrauSJjswlQydFLueCPdovYDvEZiBAIR
LwAgGqHtLrpqicx
inBvDmij
    WgqeDRRqDAp
ZYGULuCs
QKTEDOWAuPEG
DWkDmkOPLrxrCGxLNcATJcybKqAJSojLECPgvTdkbBYlIEjOXDCsnuuDgTntfHYOLnS
bpphAQnpA
BhUfreAOPXBNh
tHnQBZpVnr
DQYUEZAlYLZl
xAJeIvN
  • bnBhkGvqaOIijl
  • BszjxQWGZuroosnmvoCNKDmTTqTcKnWAUzUAincKJYuNLlvs
    UGRXLOvQVjpm
    BLADkggCLAGbwDoAKdSVEwORJFlEuespxOuvBTRBYUYWp
    | EN

    恩度®:重组人血管内皮抑制素注射液

    恩度®:重组人血管内皮抑制素注射液

    适应症:

    初治或复治Ⅲ/Ⅳ期非小细胞肺癌患者。

    抗肿瘤一类新药,全球首上市重组人血管内皮抑制素,拥有中美两国专利,获得国家技术发明二等奖及中国专利金奖,2017年起进入国家医保目录。

    *请仔细阅读说明书并在医师指导下使用